Citigroup’s Roivant Sciences ROIV Stock Holding History

Citigroup’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$956K	Hold	27,000	–	–	﹤0.01%	3474
2026 Q1	$748K	Buy	+27,000	New	+$694K	﹤0.01%	3304

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Citigroup's ROIV Position: Q2 2026 in Review

Citigroup increased its Roivant Sciences (ROIV) stake by 45% in Q2 2026, buying an estimated $20.4M and bringing the position to 2,225,190 shares worth $78.7M. The position accounts for 0.03% of the portfolio, ranked #566.

Citigroup first reported a position in ROIV in Q4 2021 and has held it in 19 quarters since. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Citigroup held 2,225,190 shares of Roivant Sciences worth $78.7M as of Q2 2026.
Citigroup bought 689,080 Roivant Sciences shares in Q2 2026, an estimated $20.4M.
Roivant Sciences made up 0.03% of Citigroup's portfolio in Q2 2026, its #566 holding.
Citigroup first reported a position in Roivant Sciences in Q4 2021 and has held it in 19 quarters since.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.